Perspectum

Perspectum, a global medical technology company with offices in the UK, the US and Singapore, delivers leading digital technologies that help clinicians provide better care for patients with chronic metabolic diseases, multi-organ pathologies and cancer. With a strong focus on precision medicine using advanced imaging and genetics, our vision is to empower patients and clinicians through quantitative assessments of health enabling early detection, diagnosis and targeted treatment. With a diverse team of physicians, biomedical scientists, engineers and technologists, Perspectum offers a way to manage complex health problems at scale. 

About us: 

Perspectum was founded in partnership with Oxford University in 2012, and now offers products and services with regulatory clearances in over 30 countries. 

Highlights : 

• LiverMultiScan (FDA 510(k) cleared and CE marked) is a patent-protected diagnostic technology for evaluating liver diseases, using MRI. Combining the information from multiple parametric maps, including Perspectum’s proprietary fibroinflammatory biomarker cT1, LiverMultiScan provides a comprehensive analysis of liver tissue, which can be used to aid the diagnosis of liver disorders. This information is provided through software-as-a-service, in an easy-to-read report delivered directly to the physician or sponsor. LiverMultiScan is available clinically in several countries including Singapore, Hong Kong, the United Kingdom and the United States. As a proven endpoint in fatty liver disease trials, LiverMultiScan is also used by pharmaceutical companies to speed NASH drug development.
  
  

•  
• Hepatica - Perspectum’s first product for cancer treatment decision support, cleared by the FDA in 2021. Hepatica integrates seamlessly into routine pre-operative MRI assessment and is the only tool that combines pre-surgical measurements of liver health with AI-driven liver volumetry, providing actionable information to inform surgical decision-making and improve patient care. Reports from Hepatica provide hepatobiliary surgeons with quantitative metrics that can be employed to evaluate overall patient liver health prior to surgery.  
  
  
  
• Perspectum launched CoverScan as the world’s first integrated multi-organ imaging service for long-COVID. The UK’s MHRA approved the using CoverScan in January 2021 to examine the long-term effects of Covid-19. CoverScan is a multi-parametric MRI suite encompassing the analysis of multiple organs from a single imaging procedure. It presents a non-invasive and cost-effective solution for accelerated stratification of patients into appropriate care pathways, and subsequently monitoring effects of treatment. 
  
  
• MRCP+ - an advanced biliary visualization software, is a ground-breaking quantitative imaging tool that enables computational techniques to enhance MRCP images. MRCP+ combines true 3D rendering of enhanced data with quantitative characterization, facilitating clear mapping of the biliary tree and pancreatic duct to show indications of disease. MRCP+ is available clinically, with FDA 510(k) clearance and CE marking.
  
  
  
  
  
  
  Website: 
  
  Schedule a 1:1 business networking meeting with Perspectum